Ali Y.A. Saleh (1)
Urinary tract infections (UTIs) represent one of the most common bacterial infections worldwide, with over 150 million cases annually, causing significant health and economic burdens. Cephalosporins, a class of β-lactam antibiotics, are widely prescribed for UTIs due to their broad-spectrum activity and low toxicity; however, increasing resistance limits their effectiveness. Despite their extensive use, little is known about the prevalence of resistance mechanisms such as biofilm formation and β-lactamase production in UTI pathogens against different generations of cephalosporins in Baghdad. This study aimed to evaluate the efficacy of 14 cephalosporin antibiotics against UTI-causing bacteria, with particular focus on resistance rates, biofilm formation, and β-lactamase enzyme production. From 140 bacterial isolates, Escherichia coli was the predominant pathogen (82.14%), with infections occurring more frequently in females (84.95%). Resistance to cephalosporins was high (68.5%), particularly against second-generation cefuroxime (97.8%), whereas cefepime, a fourth-generation antibiotic, showed the highest sensitivity (30%). Biofilm production was detected in 62.2% of isolates, while β-lactamase production was observed in 63.5%, both contributing to multidrug resistance. This research provides the first comprehensive evaluation of cephalosporin efficacy against UTI pathogens in Baghdad, combining antimicrobial susceptibility testing with virulence factor analysis. The findings highlight the urgent need for continuous surveillance of antibiotic resistance, rational prescription practices, and consideration of advanced-generation cephalosporins or alternative therapies to manage UTIs effectively.
Highlights:
[1] K. Bhargava, G. Nath, A. Bhargava, R. Kumari, G. K. Aseri, and N. Jain, “Bacterial profile and antibiotic susceptibility pattern of uropathogens causing urinary tract infection in the eastern part of Northern India,” Front. Microbiol., vol. 13, p. 965053, 2022.
[2] M. Shahzad, E. M. Khan, O. Q. Khan, U. B. Tariq, and A. Sabahat, “Urinary tract infections: Epidemiology, mechanisms of infection, and treatment,” Pak. J. Med. Health Sci., vol. 16, no. 10, pp. 810–810, 2022.
[3] A. T. Abdulkarem, S. M. Zainulabdeen, and S. M. Abed, “Overview of urinary tract infection caused by bacteria,” 2023.
[4] D. S. Kim and J. W. Lee, “Urinary tract infection and microbiome,” Diagnostics, vol. 13, no. 11, p. 1921, 2023.
[5] Y. Zhou, Z. Zhou, L. Zheng, Z. Gong, Y. Li, Y. Jin, and M. Chi, “Urinary tract infections caused by uropathogenic Escherichia coli: mechanisms of infection and treatment options,” Int. J. Mol. Sci., vol. 24, no. 13, p. 10537, 2023.
[6] H. Al Lawati, B. M. Blair, and J. Larnard, “Urinary tract infections: core curriculum 2024,” Am. J. Kidney Dis., vol. 83, no. 1, pp. 90–100, 2024.
[7] M. D. Mehmood et al., “An assessment of various disinfectants using the Kirby-Bauer Method with disc diffusion to determine their effectiveness against locally isolated pathogens,” J. Drug Deliv. Ther., vol. 14, no. 6, pp. 143–149, 2024, doi: 10.22270/jddt.v14i6.6612.
[8] W. S. El Naghy, S. A. Hamam, T. A. Wasfy, and S. M. Samy, “Detection of biofilm formation by different bacterial isolates of contact lens,” Egypt. J. Med. Microbiol., vol. 29, no. 4, pp. 93–100, 2020.
[9] A. R. S. Putra, M. H. Effendi, and F. Kurniawan, “Investigation of extended spectrum beta-lactamase (ESBL) producing Escherichia coli by Vitek-2 on dairy cows in Surabaya, Indonesia,” Biochem. Cell. Arch., vol. 20, no. 2, 2020.
[10] K. H. Liao, “Urinary tract infections caused by uropathogenic Escherichia coli: mechanisms of infection and treatment options,” Int. J. Mol. Sci., vol. 24, no. 13, p. 10537, 2023.
[11] M. H. Bhat et al., “Gender differences in the clinical profile of sodium-glucose cotransporter-2 inhibitor-related urinary tract infections,” Cureus, 2024.
[12] S. V. Lauridsen, R. Vaabengaard, R. Zeeberg, L. N. Jacobsen, and S. Islamoska, “Females have a higher risk of urinary tract infections and experience more worries than males,” Int. J. Urol. Nurs., vol. 18, no. 2, 2024.
[13] C. Zagaglia, M. G. Ammendolia, L. Maurizi, M. Nicoletti, and C. Longhi, “Urinary tract infections caused by uropathogenic Escherichia coli strains—New strategies for an old pathogen,” Microorganisms, vol. 10, no. 7, p. 1425, 2022.
[14] V. Garcia-Bustos, M. D. Cabañero-Navalón, and M. S. Lletí, “Resistance to beta-lactams in Gram-negative bacilli: relevance and potential therapeutic alternatives,” Rev. Esp. Quimioter., vol. 35, Suppl. 2, p. 1, 2022.
[15] X. Lin and U. Kück, “Cephalosporins as key lead generation beta-lactam antibiotics,” Appl. Microbiol. Biotechnol., vol. 106, no. 24, pp. 8007–8020, 2022.
[16] Y. C. Feng et al., “Distribution and genomic characterization of third-generation cephalosporin-resistant Escherichia coli isolated from a single family and home environment: a 2-year longitudinal study,” Antibiotics, vol. 11, no. 9, p. 1152, 2022.
[17] A. H. Araten et al., “Cephalosporin resistance, tolerance, and approaches to improve their activities,” J. Antibiot., vol. 77, no. 3, pp. 135–146, 2024.
[18] D. M. Jabir, “Evaluation of the ability of some bacterial species isolated from UTI to form biofilm,” Al-Qadisiyah J. Pure Sci., vol. 27, no. 1, pp. 8–14, 2022.
[19] G. M. Abebe, “The role of bacterial biofilm in antibiotic resistance and food contamination,” Int. J. Microbiol., vol. 2020, no. 1, p. 1705814, 2020.
[20] D. Balbuena-Mendoza et al., “The cephalosporin-resistant bacterial strains from urinary tract,” World J. Adv. Res. Rev., vol. 17, no. 1, pp. 97–105, 2023.
[21] E. H. Adator et al., “A One Health comparative assessment of antimicrobial resistance in generic and extended-spectrum cephalosporin-resistant Escherichia coli from beef production, sewage and clinical settings,” Microorganisms, vol. 8, no. 6, p. 885, 2020.
[22] M. Costa, M. Cardo, P. Soares, M. C. d’Anjo, and A. Leite, “Multi-drug and β-lactam resistance in Escherichia coli and food-borne pathogens from animals and food in Portugal, 2014–2019,” Antibiotics, vol. 11, no. 1, p. 90, 2022.